康复新对种植体支持康复期间牙周炎患者牙周和咀嚼功能的影响
Effects of Kangfuxin on periodontal and masticatory outcome in periodontitis patients during implant supported rehabilitation.
摘要(中文译文)
慢性牙周炎会增加种植体周围疾病风险并损害咀嚼功能。康复新液是一种具有抗炎特性的中药，在牙周治疗中已显示出疗效，但在种植体周围疾病预防方面尚未得到评估。本研究评估了其为期6个月对种植体周围健康和咀嚼功能的影响。本回顾性队列纳入300例慢性牙周炎患者（平均年龄52.3 ± 8.7岁；56%为男性），均为部分牙列缺损并接受种植修复，在2019年1月至2024年6月期间辅助使用康复新液至少6周。主要结局为探诊深度（PD）和临床附着水平（CAL）的变化。次要结局包括种植体周围炎发生率、边缘骨丢失（MBL）、咬合力、混合能力指数（MAI）和炎症生物标志物（n = 80）。6个月时，平均PD从4.8 ± 0.6 mm降至3.4 ± 0.5 mm（P < 0.001），CAL从5.1 ± 0.8 mm降至4.0 ± 0.7 mm（P < 0.001）。种植体周围炎发生率为3.0%（对比历史基准12%，P = 0.001）。MBL平均为0.28 ± 0.12 mm（94.7% < 0.5 mm）。咬合力提高39.6%（P < 0.001），MAI从48.3 ± 9.2提高至61.4 ± 7.8（P < 0.001）。IL-1β、IL-6和TNF-α均显著下降（均P < 0.001）。重度牙周炎和康复新液暴露时间延长（≥9周）显示PD降低更优。不良事件极少（1.3%为轻度黏膜刺激）；种植体存活率为99.6%。辅助使用康复新液在6个月时显著改善种植体周围参数和咀嚼功能，且安全性良好。有必要开展随机试验以确立其在高风险种植患者中的作用。
Abstract
Chronic periodontitis increases peri-implant disease risk and compromises masticatory function. Kangfuxin solution, a traditional Chinese medicine with anti-inflammatory properties, has shown efficacy in periodontal therapy but remains unevaluated in peri-implant disease prevention. This study assessed its 6-month effects on peri-implant health and masticatory function. This retrospective cohort included 300 chronic periodontitis patients (mean age 52.3 ± 8.7 years; 56% male) with partial edentulism who received implant rehabilitation with adjunctive Kangfuxin solution for a minimum of 6 weeks between January 2019 and June 2024. Primary outcomes were changes in probing depth (PD) and clinical attachment level (CAL). Secondary outcomes included peri-implantitis incidence, marginal bone loss (MBL), bite force, mixing ability index (MAI), and inflammatory biomarkers ( = 80). At 6 months, mean PD decreased from 4.8 ± 0.6 mm to 3.4 ± 0.5 mm ( < 0.001) and CAL from 5.1 ± 0.8 mm to 4.0 ± 0.7 mm ( < 0.001). Peri-implantitis incidence was 3.0% (vs. 12% historical benchmark, = 0.001). MBL averaged 0.28 ± 0.12 mm (94.7% < 0.5 mm). Bite force improved by 39.6% ( < 0.001) and MAI from 48.3 ± 9.2 to 61.4 ± 7.8 ( < 0.001). IL-1β, IL-6, and TNF-α decreased significantly (all < 0.001). Severe periodontitis and prolonged Kangfuxin exposure (≥9 weeks) showed superior PD reduction. Adverse events were minimal (1.3% mild mucosal irritation); implant survival was 99.6%. Adjunctive Kangfuxin solution significantly improved peri-implant parameters and masticatory function at 6 months with favorable safety. Randomized trials are warranted to establish its role in high-risk implant patients.
如何引用
AMA
Jiaqing Sun, Hao Zhou. Effects of Kangfuxin on periodontal and masticatory outcome in periodontitis patients during implant supported rehabilitation.. Frontiers in medicine. 2026; doi:10.3389/fmed.2026.1798184.
APA
Jiaqing Sun, Hao Zhou (2026). Effects of Kangfuxin on periodontal and masticatory outcome in periodontitis patients during implant supported rehabilitation.. Frontiers in medicine. https://doi.org/10.3389/fmed.2026.1798184
GB/T 7714
Jiaqing Sun, Hao Zhou. Effects of Kangfuxin on periodontal and masticatory outcome in periodontitis patients during implant supported rehabilitation.[J]. Frontiers in medicine, 2026 doi:10.3389/fmed.2026.1798184.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出